Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Oakmark Global Select Fund David G. Herro, Tony Coniaris, Eric Liu, M. Colin Hudson, John A. Sitarz | “IQVIA Holdings ($IQV), representing 6.9% of the fund's assets, is a leading provider of data analytics, technology solutions, and outsourced clinical research services to the life sciences and healthcare industries. The manager maintains a strong bullish stance on the company, viewing it as an indispensable partner for pharmaceutical developers navigating increasingly complex drug development pipelines. Strong quarterly performance reinforced the thesis that biopharma client demand and contract win rates are accelerating. The company's competitive advantage is anchored in its massive proprietary healthcare data pool and entrenched clinical research infrastructure, which create insurmountable barriers to entry and high customer switching costs. These advantages grant IQVIA dependable pricing power and recurring revenue stability. Additionally, management demonstrated shareholder-friendly capital allocation by opportunistically repurchasing $950 million of stock during first-half price weakness, driving per-share intrinsic value growth while operating leverage expands profitability. Key forward-looking catalysts include sustained double-digit bookings growth, margin expansion fueled by internal AI-driven productivity gains, and broader enterprise adoption of its tech-enabled clinical solutions. Downside risks to monitor include potential cancellations or deferrals of clinical trials and broader macro constraints impacting early-stage biotech research funding.” | BULL | Q3 2026 Oct 13, 2026 | View Pitch |
Oakmark Global Fund David G. Herro, Tony Coniaris, Eric Liu, M. Colin Hudson, John A. Sitarz | “IQVIA Holdings ($IQV), representing 3.3% of the fund's net assets, is a leading global provider of advanced data analytics, clinical research services, and technology infrastructure to life sciences and biopharmaceutical enterprises. The manager holds an established bullish stance, predicated on accelerating organic revenue and double-digit bookings growth that signals a robust demand inflection and rising enterprise win rates. Financially, IQVIA benefits from a powerful economic moat anchored in proprietary healthcare datasets and high customer switching costs inherent to complex, multi-year clinical trials. This operational leverage translates into strong free cash flow generation, which management has actively utilized to compound shareholder value through opportunistic capital allocation, including $950 million in share repurchases during the first half of the year. Near-term catalysts include client adoption of proprietary AI-enabled research platforms that drive clinical productivity and expand operating margins. Primary downside risks encompass potential biopharma R&D budget cutbacks, regulatory scrutiny, and delays in clinical contract execution.” | BULL | Q3 2026 Oct 13, 2026 | View Pitch |
Broyhill Asset Management Christopher R. Pavese | “IQVIA Holdings ($IQV) is a global leader in clinical research outsourcing, advanced healthcare analytics, and pharmaceutical commercial intelligence. Broyhill holds a high-conviction bullish stance, arguing that the market has mistakenly penalized IQVIA over generalized fears that artificial intelligence would disintermediate contract research organizations, overlooking the indispensability of its regulated proprietary clinical data. IQVIA's economic moat stems from its immense data assets, spanning over 1.2 billion non-identified patient records covering approximately 90% of worldwide prescription activity. This proprietary data repository cannot be easily replicated by generic AI algorithms, providing the company with strong pricing power and high client retention. Financially, an upcoming $300 billion pharmaceutical patent cliff acts as a structural tailwind, forcing drugmakers to aggressively invest in R&D and clinical trials to refill drug pipelines, which fueled a book-to-bill ratio of 1.22x in the second quarter. Upcoming catalysts include sustained improvement in RFP flows, clinical award delivery, and continued clinical trial bookings expansion. Key risks include macroeconomic cutbacks in discretionary biotech R&D budgets and prolonged regulatory trial approval timelines.” | BULL | Q2 2026 Sep 1, 2026 | View Pitch |
BESTINVER Mark Giacopazzi | “IQVIA Holdings ($IQV) is a leading global contract research organization (CRO) and healthcare data analytics provider formed through the merger of Quintiles and IMS Health. The company assists biopharmaceutical sponsors in designing, running, and analyzing clinical trials. The manager's bullish thesis contends that the market mistakenly views IQVIA as a structural loser threatened by artificial intelligence, causing the stock to trade at an unwarranted 30% discount despite accelerating operational revenue growth, record cash generation, and an expanding clinical trial pipeline. From an economic standpoint, IQVIA operates as an irreplaceable data toll road protected by an immense moat: a proprietary longitudinal database of more than 1.2 billion patient records in a strictly regulated environment. While algorithms can be replicated, proprietary clinical datasets cannot. Furthermore, by driving a 15% to 20% cost reduction in drug development, AI acts as an operational volume catalyst rather than a disintermediary, inducing pharmaceutical companies to reinvest cost savings into higher numbers of clinical trials. The company trades at an attractive valuation multiple of approximately 14x forward earnings, 11x EV/EBITDA, and a 7% free cash flow yield with 100% cash conversion. Key upside catalysts include biotech funding recovery, accelerated pipeline conversion from its $34.2 billion backlog, multi-product client expansions, and ongoing share buybacks exceeding $500 million per quarter. Major downside risks include contract pricing pressure from consolidated pharmaceutical giants, potential regulatory trial delays, and general volatility in emerging biotech capital markets.” | BULL | Q2 2026 Jun 30, 2026 | View Pitch |
Sycamore Mid Cap Value Equity Gary H. Miller | “The company's shares fell due to conservative guidance and investor anxiety regarding artificial intelligence's impact on clinical trial workflows. The manager believes these fears are currently unproven by data and notes stabilizing biotech funding trends.” | BULL | Q1 2026 Mar 31, 2026 | View Pitch |
Broyhill Asset Management Christopher R. Pavese | “IQVIA contributed meaningfully as fears around biotech funding and clinical activity began to ease. While sentiment toward the sector remains fragile, the company's role as a mission-critical infrastr” | BULL | Q4 2025 Feb 17, 2026 | View Pitch |
Broyhill Asset Management Christopher R. Pavese | “IQVIA contributed meaningfully as fears around biotech funding and clinical activity began to ease. While sentiment toward the sector remains fragile, the company's role as a mission-critical infrastructure to drug development remains unchallenged. The first leg of the industry's recent rally was sparked by stabilization, rewarding patience through a prolonged industry downturn. We expect the next leg to gain steam as the recovery accelerates. BSD Analysis: IQVIA remains a dominant force in the life sciences sector, uniquely combining its massive healthcare data assets with industry-leading clinical research services. The company is currently trading at a notable discount to its fair value, presenting a tactical opportunity as it benefits from a surge in high-value clinical trials within the obesity and cardiometabolic space. While debt coverage remains a metric for investors to watch, IQVIA's strategic alliance with major research institutions and its AI-driven analytics platform provide a wide competitive moat. Management's focus on high-growth therapeutic areas and digital clinical trials is expected to drive meaningful margin expansion as the biotech funding environment continues to stabilize. With a valuation significantly below its historical average and peer group, the stock offers an attractive entry point for investors seeking exposure to the long-term digitization of global healthcare.” | BULL | Q4 2025 Feb 17, 2026 | View Pitch |
Harris Associates Concentrated Strategy Tony Coniaris | “IQVIA Holdings was a contributor during the quarter. The U.S.-headquartered provider of advanced analytics, solutions, and clinical research services saw its stock price appreciate after having delivered solid second-quarter results amidst a challenging pharma environment. The results reaffirmed our thesis that the technology and analytics solutions (TAS) segment is underappreciated and poised for future growth. Further the R&D solutions business showed signs of gaining share, with its win rate improving significantly. We believe forward-looking indicators are encouraging and think the company can extract further value as it leverages next-gen trends. BSD Analysis: Harris highlights IQVIA's mix of stable analytics revenue and cyclical R&D tailwinds. With EV/EBITDA ~14x and steady margin expansion, the TAS segment is driving multiple re-rating potential. Digital trials, AI-driven data use, and recurring software sales reinforce visibility.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Harris Associates Concentrated Strategy Tony Coniaris | “IQVIA was a contributor during the quarter. The U.S.-headquartered life sciences services and analytics company's stock price rose following solid first-quarter 2025 results and an improved outlook. Management emphasized continued demand for data, analytics and technology solutions from biopharma clients as well as a healthy backlog in its contract research operations. The managers believe IQVIA remains well positioned to benefit from structural growth in outsourced clinical development and real-world evidence. They continue to view the company as an attractive compounder with strong competitive advantages and high switching costs. BSD Analysis: IQVIA sits at the intersection of data, software and services for pharma and biotech customers, underpinning a durable growth profile as R&D complexity increases. Its broad data assets and integrated technology stack create a sticky ecosystem that is difficult for competitors to replicate. Despite periodic biopharma funding cycles, long-term demand for outsourced clinical and evidence-generation services remains robust. Valuation reflects its quality and growth, but continued margin expansion and disciplined capital allocation can sustain attractive returns.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.